Each scored tablet contains:
Ezetimibe 10 mg.
Ezetimibe appears to act at the brush border of the small intestine and inhibits the intestinal absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood.
Zetamibe reduces total-C, LDL-C, Apo B, and TG, and increases HDL-C in patients with hypercholesterolemia. Administration of Zetamibe with an HMG-CoA reductase inhibitor shows better results than either treatment alone.
-Primary hypercholesterolemia (heterozygous familial and nonfamilial), as monotherapy or in combination with an HMG-CoA reductase inhibitor to reduce elevated cholesterol, low density lipoproteins and triglycerides, in adjunction to diet.
-In patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments.
Generally the recommended dose is one tablet of Zetamibe once daily, with or without food.
Zetamibe may be administered with an HMG-CoA reductase inhibitor (at the same time of the day) for incremental effect.
Hypersensitivity to any component of this medication.
The use of Zetamibe with HMG-CoA reductase inhibitors is contraindicated with active liver disease or unexplained persistent elevations of serum transaminases.
The Drug is generally well tolerated.
Box contains 10 scored tablets in one strip.